Affiliation:
1. October 6 University
2. Cairo University Faculty of Pharmacy
3. Misr University for Science and Technology College of Pharmacy
4. Fayoum University
Abstract
Abstract
In the present work seeks to address the role of
nanoencapsulated platform of Coenzyme Q10 (coQNPs) or selenium
(SeNPs) in hyperlipidemia and alleviation of simvastatin-induced
myopathy and adverse reactions. Physicochemical characters and zeta
potential studies for solid nanoparticles (SLNPs), coQNPs and SeNPs
were performed. Male Wistar albino rats were treated for 112 days
with either (i) nano-vehicle only (ii) high fat diet (HFD) (iii)
HFD + SV (20 mg/kg/day, P.O.) alone or (iv) with coQNPs
(10mg/Kg/day, P.O.) or (v) / and (vi) SeNPs (0.1 mg/Kg/day, P.O.)
for last 30 days. CoQNPs and SeNPs were shown in a uniform
spherical shape with EE% 91.20 ±2.14, 94.89 ±1.54, respectively.
HFD resulted in severe changes in all tested parameters that
affirmed with histopathological results. Treatment with SV and
CoQNPs/ or SeNPs exhibited a prominent restoring of all measured
patterns, but the triple combination of SV, CoQNPs, and SeNPs
exhibited an intense hepatic and muscular injury. SV and SeNPs
treatment showed a pronounced improvement like control itself.
These results represent that CoQNPs or SeNPs platforms showed
advanced alleviation of hyperlipidemia, insulin resistance, with a
direct limitation for its adverse effects such as myopathy and
hepatotoxicity.
Publisher
Research Square Platform LLC